44 articles for thisTarget
The following articles (labelled with PubMed ID or TBD) are for your review
PMID
Data
Article Title
Organization
Inhibition of Histone Demethylases Offers a Novel and Promising Approach for the Treatment of Cancer and Other Diseases.
Therachem Research Medilab (India)
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 1. 3-Amino-4-pyridine Carboxylate Derivatives.
Glaxosmithkline
Docking and Linking of Fragments To Discover Jumonji Histone Demethylase Inhibitors.
University of Oxford
Cell Penetrant Inhibitors of the KDM4 and KDM5 Families of Histone Lysine Demethylases. 2. Pyrido[3,4-d]pyrimidin-4(3H)-one Derivatives.
Glaxosmithkline
Identification of Jumonji AT-Rich Interactive Domain 1A Inhibitors and Their Effect on Cancer Cells.
Kyoto Prefectural University of Medicine
Identification of the KDM2/7 histone lysine demethylase subfamily inhibitor and its antiproliferative activity.
Kyoto Prefectural University of Medicine
Inhibitor scaffold for the histone lysine demethylase KDM4C (JMJD2C).
University of Copenhagen
Design, synthesis, enzyme-inhibitory activity, and effect on human cancer cells of a novel series of jumonji domain-containing protein 2 histone demethylase inhibitors.
Nagoya City University
Structure-Based Design of Selective Fat Mass and Obesity Associated Protein (FTO) Inhibitors.
University of Oxford
Recent Advances with KDM4 Inhibitors and Potential Applications.
St. Jude Children'S Research Hospital
Drug discovery of histone lysine demethylases (KDMs) inhibitors (progress from 2018 to present).
Hangzhou Normal University
Discovery of pyrazole derivatives as cellular active inhibitors of histone lysine specific demethylase 5B (KDM5B/JARID1B).
Zhengzhou University
Lead optimization of a pyrazolo[1,5-a]pyrimidin-7(4H)-one scaffold to identify potent, selective and orally bioavailable KDM5 inhibitors suitable for in vivo biological studies.
Genentech
Optimisation of a triazolopyridine based histone demethylase inhibitor yields a potent and selective KDM2A (FBXL11) inhibitor.
University of Oxford
Pan-histone demethylase inhibitors simultaneously targeting Jumonji C and lysine-specific demethylases display high anticancer activities.
Sapienza University of Rome
Targeting lysine specific demethylase 4A (KDM4A) tandem TUDOR domain - A fragment based approach.
Abbvie
Design of KDM4 Inhibitors with Antiproliferative Effects in Cancer Models.
Celgene Quanticel Research
Structure-activity studies of a macrocyclic peptide inhibitor of histone lysine demethylase 4A.
The University of Tokyo
From a novel HTS hit to potent, selective, and orally bioavailable KDM5 inhibitors.
Genentech
In search of new a-glucosidase inhibitors: Imidazolylpyrazole derivatives.
University of The Punjab
The mouse 5HT5 receptor reveals a remarkable heterogeneity within the 5HT1D receptor family.
Cnrs
Calorimetric Studies on the Complexation of Several Ferrocene Derivatives by .alpha.- and .beta.-Cyclodextrin. Effects of Urea on the Thermodynamic Parameters
University of Miami
Carbonic anhydrase inhibitors. Interaction of the antitumor sulfamate EMD 486019 with twelve mammalian carbonic anhydrase isoforms: Kinetic and X-ray crystallographic studies.
Universita Degli Studi Di Firenze
Pyridone derivatives as potent, orally bioavailable VLA-4 integrin antagonists.
Glaxosmithkline